Mark Eisner
Direttore Tecnico/Scientifico/R&S presso VIR BIOTECHNOLOGY, INC.
Patrimonio netto: 142 646 $ in data 30/06/2024
Profilo
Il Dr. Mark Eisner, MD, è il responsabile medico di FibroGen, Inc. Il Dr. Eisner è stato precedentemente impiegato come vicepresidente senior presso Genentech, Inc. e professore presso l'Università della California, San Francisco. Ha conseguito la laurea presso la Stanford University, il dottorato presso la UC Berkeley School of Public Health e il dottorato presso la University of Pennsylvania Medical Center.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
FIBROGEN, INC.
0.16% | 06/09/2023 | 159 917 ( 0.16% ) | 142 646 $ | 30/06/2024 |
Posizioni attive di Mark Eisner
| Società | Posizione | Inizio |
|---|---|---|
| VIR BIOTECHNOLOGY, INC. | Direttore Tecnico/Scientifico/R&S | 03/06/2024 |
| The Genentech Foundation | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Mark Eisner
| Società | Posizione | Fine |
|---|---|---|
| FIBROGEN, INC. | Direttore Tecnico/Scientifico/R&S | 08/09/2023 |
Sonoma Biotherapeutics, Inc.
 Sonoma Biotherapeutics, Inc. BiotechnologyHealth Technology Sonoma Biotherapeutics, Inc. provides research, development, and manufacturing capabilities in cell therapy and genetic engineering. The company was founded by Jeffrey A. Bluestone, Fred Ramsdell, Alexander Rudensky, and Qizhi Tang in 2019 and is headquartered in South San Francisco, CA. | Direttore Tecnico/Scientifico/R&S | - |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
| The University of California, San Francisco | Corporate Officer/Principal | - |
Formazione di Mark Eisner
| Stanford University | Undergraduate Degree |
| University of Pennsylvania Medical Center | Doctorate Degree |
| UC Berkeley School of Public Health | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| FIBROGEN, INC. | Health Technology |
| VIR BIOTECHNOLOGY, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
| The Genentech Foundation | Miscellaneous |
Sonoma Biotherapeutics, Inc.
Sonoma Biotherapeutics, Inc. BiotechnologyHealth Technology Sonoma Biotherapeutics, Inc. provides research, development, and manufacturing capabilities in cell therapy and genetic engineering. The company was founded by Jeffrey A. Bluestone, Fred Ramsdell, Alexander Rudensky, and Qizhi Tang in 2019 and is headquartered in South San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Mark Eisner
